Home Featured Page 262

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

MYND Life Sciences Inc. Establishes Scientific Advisory Board

The Psilocybin vs. Escitalopram Trial – Part 1

Renowned Psychedelic Researcher, James Fadiman, PhD, Joins Wesana Health Scientific Advisory...

PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain...

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug...

Field Trip Health Ltd. Receives Conditional Approval to Up-List to the...

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data...

Healing Trip Tales: One Vet’s Ibogaine & 5-MeO-DMT Experience for PTSD...

MYND Life Sciences Inc. Announces Public Listing on the Canadian Securities...

Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative...

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.